Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iBio, a biopharmaceutical company, has granted rights to use its proprietary technology iBioLaunch platform, in support of a $5.3m government-funded project for the development of a single vaccine to protect against both anthrax and plague.
Subscribe to our email newsletter
The project is expected to be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology.
Additionally, iBio and CMB have developed a new biologics production platform based on the use of green plants to manufacture vaccines and therapeutic proteins. The technology has been successfully applied to a variety of candidate products, including an avian influenza vaccine planned to be the first product to enter a human clinical trial in 2010.
Robert Kay, chairman and CEO of iBio, said: “We believe this program will further demonstrate the ability of our technology to produce novel products rapidly, effectively and economically.”
Vidadi Yusibov, executive director of CMB, said: “We are confident in our ability to deliver on the objective of this contract. We expect to demonstrate the safety and efficacy of a one-shot vaccine in animal tests in preparation for clinical development.”